TURKISH JOURNAL OF ONCOLOGY 1997 , Vol 12 , Num 3
EVALUATION OF RESULTS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER, COMBINATION OF DAILY LOW DOSE CISPLATIN AND ACCELERATED CONCOMITANT BOOST RADIOTHERAPY
SÜREYYA SARIHAN, EMİN DARENDELİLER, AHMET KİZİR, NİNA TUNCEL, İSMAİL ÖZBAY, NURİ TENEKECİ, PINAR SAİP, ETHEM NEZİH ORAL, RİAN DİŞÇİ, AHMET KARADENİZ, NİJAD BİLGE
Uludağ Üniversitesi, Radyasyon Onkolojisi AD., Bursa A prospective phase II trial, using combination of cisplatin as a radiosensitizer and accelerated concomitant boost radiotherapy was started by Institute of Oncology, İstanbul University, in December 1994; on patients with locally advanced non-small cell lung cancer. "Large" field was irradiated 5 days a week and followed after at least 6 hours, two times weekly to reduced "boost" field, given from the beginning of the therapy. Cisplatin was administered 6 mg per square meter, given daily 1 hour before each "large" field irradiation by 1 hour infusion. In January 1997, a small group of 15 patients were evaluated. An overall acute toxicity rate was 38%. It was considered that early and increased skin reactions may be due to radiosensitizer effect of cisplatin. Toxicity of esophagus was acceptable. Grade 4 toxicity was not seen in any patient. Cisplatin induced nausea and vomiting were seen of 80%, but could be treated with antiemetics. Complete response rate, observed radiologically was achieved by 40%, and median survivial was 16 months. It was thought that this combined modality treatment schedule could be feasible, acute toxicity could be well tolerated and a better complete response rate could be obtained. Keywords :